John G. Kuhn - Concepedia

Author

John G. Kuhn

The University of Texas Health Science Center at San Antonio ORCID

Also Known As

Chen, H Haoshuo, Donna R. Degen, Hu Chen, J G Kuhn, J Kuhn, J. G. KUHN, J. G. Kuhn, J. Kuhn, J.G. Kuhn, JOHN G. KUHN

306

Publications

12.3K

Citations

H-Index

124

Concepts

All Affiliations

The University of Texas Health Science Center at San Antonio University of California, San Francisco The University of Texas MD Anderson Cancer Center Dana-Farber Cancer Institute Brooke Army Medical Center

About

John G. Kuhn is an author at The University of Texas Health Science Center at San Antonio specializing in medicine, pharmacology, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	38	67	5K
2	Health Sciences	9	9	1K
3	Natural Sciences	6	6	364
4	Engineering	3	3	191
5	Education	1	1	58

John G. Kuhn

143

Publications

11.3K

Citations

H-Index

Page 1

	Year	Citations
Progression-free survival: An important end point in evaluating therapy for recurrent high-grade gliomas Kathleen R. Lamborn, W.K. Alfred Yung, Susan M. Chang, Neuro-Oncology Progression-free SurvivalGrade Iii GliomasCancer ManagementPrognosisImportant End Point	2008	416
Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme Susan M. Chang, Patrick Y. Wen, Timothy F. Cloughesy, Investigational New Drugs Neuro-oncologyTumoral PathologyGliomaMedicineRecurrent Glioblastoma Multiforme	2005	400
Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. Mace L. Rothenberg, John R. Eckardt, John G. Kuhn, Journal of Clinical Oncology	1996	351
Differential Sensitivity of Glioma- versus Lung Cancer–Specific EGFR Mutations to EGFR Kinase Inhibitors Igor Vivanco, H. Ian Robins, Daniel Rohle, Cancer Discovery	2012	336
EGFR Signaling Through an Akt-SREBP-1–Dependent, Rapamycin-Resistant Pathway Sensitizes Glioblastomas to Antilipogenic Therapy Deliang Guo, Robert M. Prins, Julie Dang, Science Signaling	2009	335
Phase I and pharmacokinetic trial of weekly CPT-11. Mace L. Rothenberg, John G. Kuhn, Howard A. Burris, Journal of Clinical Oncology Therapeutic Drug MonitoringOncologyDrug InfusionHealth SciencesDose Levels	1993	301
Pharmacokinetics of itraconazole following oral administration to normal volunteers T C Hardin, John R. Graybill, Richard J. Fetchick, Antimicrobial Agents and Chemotherapy Antifungal AgentPharmacological StudyMedicineAntifungal AgentsHealthy Male Volunteers	1988	296
A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy Jeffery J. Raizer, L. E. Abrey, Andrew B. Lassman, Neuro-Oncology PharmacotherapyHigh-grade GliomasGliomaNeuro-oncologyOncology	2009	294
A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: A North American Brain Tumor Consortium study1 Michael D. Prados, Kathleen R. Lamborn, W. K. Alfred Yung, Neuro-Oncology	2006	254
Molecular Study of Malignant Gliomas Treated with Epidermal Growth Factor Receptor Inhibitors: Tissue Analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01 Andrew B. Lassman, Michael R. Rossi, Jeffrey R. Razier, Clinical Cancer Research	2005	246

Page 1